MARKHAM, ON, Sept. 2 /CNW/ - Cytochroma today announced that Charles W.
Bishop, PhD, President and CEO, will be presenting a corporate overview at the
following investor conferences:
- Baird's 2009 Health Care Conference at 12:45 PM EDT on Wednesday,
September 9, 2009 at the Four Seasons Hotel in New York City.
- Thomas Weisel Partners' 2009 Healthcare Conference at 10:20 AM EDT on
Friday, September 11, 2009 at the Four Seasons Hotel in Boston.
Cytochroma is a clinical stage specialty pharmaceutical company focused
on developing and commercializing proprietary products to treat and prevent
the clinical consequences of vitamin D insufficiency and secondary
hyperparathyroidism (SHPT) associated with chronic kidney disease (CKD). The
Company specializes in developing new vitamin D therapies which are designed
to safely and effectively treat patients with stage 3, 4 or 5 CKD. Cytochroma
has three lead product candidates in clinical development for CKD patients:
CTA018 Injection and CTAP201 Injection are being developed for the treatment
of SHPT in stage 5 CKD, while CTAP101 Capsules are being developed for the
treatment of vitamin D insufficiency and associated SHPT in stage 3 and 4 CKD.
In addition, Cytochroma is developing novel therapies to treat
hyperphosphatemia in CKD patients.
For more information about Cytochroma, please visit www.cytochroma.com.
For further information:
For further information: Cytochroma Investors: Gordon Ngan, Executive
Director, Corporate Development, Tel: (905) 479-5306 ext. 333,
email@example.com; Cytochroma Media: Robert Stanislaro (FD), Tel: (212)